

Cinqair (reslizumab) Prior Authorization form (Drugs Administered in Office), fax requests to 844-639-7906

Please complete the form by providing all of the following information. Failure to fill out this form in its entirety may delay the review process. To review the Clinical Medical Policies, please visit our website at <https://www.nhpri.org/Providers/ClinicalMedicalPolicies.aspx>

MEMBER INFORMATION

Member's Name:	Member's ID #:	Member's DOB:
Member Phone Number:	Member Address:	Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female <input type="checkbox"/> Unknown Primary Language: <input type="checkbox"/> English <input type="checkbox"/> Spanish <input type="checkbox"/> Other:

REQUESTING PROVIDER INFORMATION

Provider's Name:	Provider's Phone #:	Provider's Fax #:
Date of Request:	Provider's NPI #:	Provider's Contact Name and Phone:

SERVICING PROVIDER INFORMATION (Must be filled out appropriately to ensure claim adjudication)
HOW WILL MEDICATION BE OBTAINED:

☐ Drop Ship from Specialty Pharmacy: _____ and NPI _____

☐ If Buy & Bill: Specify Provider/ Facility: _____ and NPI _____
Servicing Provider Fax#: _____

CLINICAL INFORMATION

Requested J-Code:	Requested CPT code(s):	<input type="checkbox"/> Initial Request <input type="checkbox"/> Continuation of therapy Request
Drug Name& strength:	Date(s) of Service Requested:	
Directions:	# of units:	

ICD 10 Codes:

Clinical Assessment (provide all required information and clinical documents)	YES	NO
Is the Cinqair (reslizumab) being prescribed by an Allergist or Pulmonologist?	<input type="checkbox"/>	<input type="checkbox"/>
Is the patient at least 18 years of age or older?	<input type="checkbox"/>	<input type="checkbox"/>
Does the patient have a diagnosis of severe persistent asthma and has had at least 1 hospitalization or ER visit in the previous 12 months?	<input type="checkbox"/>	<input type="checkbox"/>
Does the patient have a diagnosis of eosinophilic asthma with blood eosinophil count of ≥ 400 cells/ μ L OR is the member unable to be taken off oral steroids long enough to allow for an accurate eosinophil count?	<input type="checkbox"/>	<input type="checkbox"/>
Does the patient have poorly controlled asthma despite being adherent** to maximal therapy (high-dose ICS + LABA \pm oral corticosteroid) for ≥ 3 months? **Pharmacy claims will be reviewed for adherence to medications related to diagnosis for all requested (initial and continuation of therapy).	<input type="checkbox"/>	<input type="checkbox"/>

Continuation of therapy criteria:

- Is the patient tolerating treatment?
- Has the patient shown disease stabilization or improvement in asthma symptoms or asthma exacerbations as evidenced by decrease in one or more of the following: Use of systemic corticosteroids, two-fold or greater decrease in inhaled corticosteroids use for at least 3 days, hospitalizations, ER visits, unscheduled visits to healthcare provider or improvement from baseline in forced expiratory volume in 1 second (FEV1)?

☐
☐
☐
☐

NOTE: THIS FORM MUST BE SIGNED BY A PHYSICIAN

Signature of Requesting Provider:

Date:

Authorization is not a guarantee of payment. Member must be eligible at time of service.

Neighborhood Health Plan of Rhode Island Tel. 401-427-8200 Fax at 844-639-7906